C

Central States Research | Tulsa, OK

Research site
(Unclaimed)
Location
7318 South Yale Avenue, Tulsa, Oklahoma, United States of America
Site insights

Top conditions

Alzheimer Disease (11 trials)

Atopic Dermatitis (3 trials)

Type 2 Diabetes Mellitus (3 trials)

Dermatitis (3 trials)

Diabetes Mellitus (3 trials)

Top treatments

Troriluzole
Donanemab
Metformin
Retatrutide
Gantenerumab
Orforglipron
Cannabidiol
BI 1358894
Lecanemab
ABBV-916

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 29
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Semagludtide
Drug: Placebo (semaglutide)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Enrolling
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment a...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab
Drug: Placebo

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN00...

Enrolling
Fragile X Syndrome
Drug: Placebo
Drug: ZYN002 - transdermal gel

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ren...

Enrolling
Type 2 Diabetes
Drug: Placebo
Drug: Retatrutide

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and...

Enrolling
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Retatrutide

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery)....

Invitation-only
Fragile X Syndrome
Drug: ZYN002 - Cannabidiol Transdermal Gel

Trial sponsors

Lilly logo

Lilly (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems